Portfolio Risk
Cash runway vs days to next catalyst — spot binary event risk at a glance
| Company | Catalyst | Type | Days | Runway | Impact | Confidence |
|---|---|---|---|---|---|---|
| 1AD | Shareholder approval at EGM for options offer | Regulatory | 4d | 1mo | medium | confirmed |
| BOT | BX002 Phase 2 acne topline data | Data Readout | 19d | 3mo | high | expected |
| IMU | Potential capital raise | Financing | 19d | 2mo | medium | speculative |
| TLX | TLX250-CDx FDA submission | Regulatory | 19d | CF+ | high | expected |
| OPT | Sozinibercept Phase 3 wet AMD topline | Data Readout | 19d | 64mo | high | expected |
| 4DX | XV LVAS US reimbursement progress | Commercial | 19d | 5mo | high | expected |
| CU6 | CLARIFY trial enrolment close | Data Readout | 19d | 27mo | high | expected |
| CSL | CSL112 Phase 3 AEGIS-II readout | Data Readout | 19d | CF+ | high | expected |
| CSL | Seqirus flu vaccine season | Commercial | 19d | CF+ | medium | confirmed |
| MSB | Remestemcel-L US BLA resubmission pathway | Regulatory | 19d | 24mo | high | expected |
| PYC | VP-001 Phase 1/2 RP11 further data | Data Readout | 19d | 26mo | high | expected |
| ACW | Xanamem Phase 2 XanaMIA study data | Data Readout | 19d | 3mo | high | expected |
| NAN | CORIS endoscope reprocessing update | Commercial | 19d | CF+ | medium | expected |
| ANO | ADAPT TAVR first-in-human update | Data Readout | 19d | 0mo | high | expected |
| AVH | 7th MAC reimbursement rate publication | Regulatory | 19d | CF+ | medium | confirmed |
| CYP | CYP-001 Phase 2 aGvHD top-line results | Data Readout | 19d | 2mo | high | confirmed |
| AVH | Cohealyx I study data readout | Data Readout | 19d | CF+ | high | expected |
| AVH | Final MAC reimbursement coverage | Commercial | 19d | CF+ | high | expected |
| CUV | NEURACTHEL EMA marketing authorization filing | Other | 19d | CF+ | medium | expected |
| EBRDA | WiSE CRT pivotal trial enrolment complete | Data Readout | 19d | 12mo | high | expected |
| TLX | PHASE3 data readout — 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | Data Readout | 19d | CF+ | medium | speculative |
| PIQ | US PromarkerD revenue ramp (CMS reimbursement live Jan 2026) | Commercial | 19d | 7mo | high | confirmed |
| PIQ | PromarkerEndo Australian commercial launch | Regulatory | 19d | 7mo | medium | expected |
| MYX | RHOFADE generic competition entry | Commercial | 19d | CF+ | high | confirmed |
| NYR | NYR-BI03 Phase 1 brain injury final results | Data Readout | 19d | 23mo | medium | expected |
| RCE | RECCE 327 Phase 3 DFI interim analysis (155 patients) | Data Readout | 19d | CF+ | high | expected |
| ILA | ISLA-101 Phase 2b therapeutic cohort full data package | Data Readout | 19d | 19mo | high | expected |
| CYC | NIH and federal hospital Technegas expansion | Commercial | 19d | CF+ | medium | confirmed |
| SOM | Rest Assure clinical study completion | Data Readout | 19d | CF+ | high | expected |
| BDX | Enhanced BREASTESTplus launch (C+D density) | Commercial | 19d | CF+ | high | confirmed |
| ACR | Dapsone 7.5% Gel US launch revenue | Commercial | 19d | 2mo | medium | confirmed |
| SNT | FDA feedback on myelofibrosis development plan | Regulatory | 19d | 17mo | high | expected |
| SNT | Phase 2 MF combo (ruxolitinib) efficacy data readout | Data Readout | 19d | 17mo | high | expected |
| ADO | Battery pipeline lead conversion to JDAs/sales | Commercial | 19d | 3mo | high | speculative |
| IDT | New radiopharmaceutical CDMO contract wins | Commercial | 19d | CF+ | high | speculative |
| BIT | BIT225 licensing/partnership deal (via C14 advisory) | Commercial | 19d | 8mo | high | speculative |
| BIT | HBV preclinical efficacy data from animal models | Data Readout | 19d | 8mo | medium | expected |
| UBI | Aquascout commercial launch | Commercial | 19d | 0mo | high | expected |
| BXN | Initial Dr Watson® shipment to Costa Rica | Commercial | 19d | 0mo | medium | expected |
| MYX | Cosette appeal decision | Regulatory | 19d | CF+ | high | expected |
| AGN | WHO INN recommended status publication | Regulatory | 19d | 8mo | medium | expected |
| FPH | Trial data readout — NIV With Airway Washout for Dual Limb Ventilation: Improvement in Minute Ventila | Data Readout | 20d | CF+ | medium | speculative |
| OSL | FDA HDE final review completion and approval decision | Regulatory | 42d | CF+ | high | expected |
| NEU | NNZ-2591 Phase 2 Phelan-McDermid interim | Data Readout | 50d | CF+ | high | expected |
| CHM | CLTX CAR-T Phase 1 GBM safety data | Data Readout | 50d | 2mo | high | expected |
| TRP | TRIVIA Phase 3 interim analysis (100 patients) | Data Readout | 50d | 12mo | high | expected |
| PME | FY2026 full-year results | Other | 69d | CF+ | high | confirmed |
| SHL | FY2026 full-year results | Other | 70d | CF+ | medium | confirmed |
| PNV | NovoSorb MTX hernia trial update | Data Readout | 81d | CF+ | medium | expected |
| IDT | FY2026 full year results — potential first profitable year | Data Readout | 81d | CF+ | high | speculative |
| PAR | PARA_OA_012 Phase 3 Interim Analysis Results | Data Readout | 81d | 4mo | high | expected |
| HLS | FY2026 EBIT target test (~$48M) | Other | 81d | 0mo | high | expected |